Drug Trial Radar · NCT06571045
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
984
Actual
Start
Aug 7, 2024
Primary completion
Jul 14, 2026
Study completion Aug 14, 2027
Sponsor
- Lead sponsor
- EyeBiotech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
Conditions
- Diabetic Macular Edema (DME)
Interventions
RanibizumabDrug
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
RemigromigDrug
Remigromig is a humanized antibody formulated for intravitreal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chartTime frame: Baseline and Week 52
Locations
183 sites in 20 countries. Site status is shown where the registry gives one.
Scottsdale
Scottsdale, Arizona
Fayetteville, Arkansas
Fayetteville, Arkansas
Springdale, Arkansas
Springdale, Arkansas
Bakersfield, CA
Bakersfield, California
Glendale, CA
Glendale, California
Modesto, CA
Modesto, California
Mountain View, CA
Mountain View, California
Redlands, CA
Redlands, California
Sacramento, CA
Sacramento, California
Sacramento, CA
Sacramento, California
Santa Ana
Santa Ana, California
Colorado Springs, CO
Colorado Springs, Colorado
Denver, Colorado
Denver, Colorado
Danbury, CT
Danbury, Connecticut
Manchester, CT
Manchester, Connecticut
Waterford,CT
Waterford, Connecticut
Deerfield Beach, FL
Deerfield Beach, Florida
Fort Lauderdale, FL
Fort Lauderdale, Florida
Fort Myers,FL
Fort Myers, Florida
Gainesville, FL
Gainesville, Florida
Orlando, Florida
Orlando, Florida
Plantation, FL
Plantation, Florida
Sarasota, FL
Sarasota, Florida
Saint Petersburg, FL
St. Petersburg, Florida
Tallahassee, FL
Tallahassee, Florida
Tampa, FL
Tampa, Florida
Tampa, FL
Tampa, Florida
Winter Haven, FL
Winter Haven, Florida
Lemont, IL
Lemont, Illinois
Springfield, Illinois
Springfield, Illinois
West Des Moines, IA
West Des Moines, Iowa
Lenexa, Kansas
Lenexa, Kansas
Wichita, Kansas
Wichita, Kansas
Portland, Maine
Portland, Maine
Hagerstown, MD
Hagerstown, Maryland
Springfield,MA
Springfield, Massachusetts
Grand Rapids, Michigan
Grand Rapids, Michigan
Minneapolis, MN
Minneapolis, Minnesota
Madison, MS
Madison, Mississippi
Bloomfield, NJ
Bloomfield, New Jersey
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.